Astellas and Takeda continue to advance vaccine strategies

Japanese manufacturers Astellas and Takeda continued to advance their vaccine plans this week. Astellas, having founded a vaccine startup last week, presented summary results from Phase III trials of the Protein Sciences flu shot it plans to commercialize in Japan. Separately, Takeda signed a deal to begin selling a freeze-dried live attenuated chickenpox vaccine in Japan. Astellas' release (PDF) | Takeda's release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.